Veru Salute del bilancio

Salute finanziaria criteri di controllo 5/6

Veru ha un patrimonio netto totale di $37.6M e un debito totale di $9.6M, che porta il suo rapporto debito/patrimonio netto a 25.4%. Le sue attività totali e le sue passività totali sono rispettivamente $64.6M e $27.0M.

Informazioni chiave

25.4%

Rapporto debito/patrimonio netto

US$9.56m

Debito

Indice di copertura degli interessi	n/a
Contanti	US$29.15m
Patrimonio netto	US$37.62m
Totale passività	US$27.01m
Totale attività	US$64.63m

Aggiornamenti recenti sulla salute finanziaria

Recent updates

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( $38.5M ) di FMW superano le sue passività a breve termine ( $10.6M ).

Passività a lungo termine: Le attività a breve termine di FMW ( $38.5M ) superano le sue passività a lungo termine ( $16.4M ).

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: FMW ha più liquidità del suo debito totale.

Riduzione del debito: Il rapporto debito/patrimonio netto di FMW si è ridotto da 31.6% a 25.4% negli ultimi 5 anni.

Bilancio

Analisi della pista di contanti

Per le società che in passato sono state mediamente in perdita, valutiamo se hanno almeno un anno di liquidità.

Pista di liquidità stabile: FMW ha una pista di cassa sufficiente per più di un anno in base al suo attuale flusso di cassa libero.

Previsione Cash Runway: FMW ha meno di un anno di liquidità disponibile se il flusso di cassa libero continua a ridursi ai tassi storici del 41.8 % ogni anno

Veru Salute del bilancio

Salute finanziaria criteri di controllo 5/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

Veru Receives Notification from The Nasdaq Stock Market

Veru Receives a Notification Letter from the Listing Qualifications Department of the Nasdaq Stock Market

Veru Inc. announced delayed 10-Q filing

Veru Receives Non-Compliance Notice From Nasdaq

Recent updates

New minor risk - Market cap size

Veru Inc. Announces Meta-Analysis of Body Composition Data from Older Patients with Obesity Which Supports Potential for Enobosarm to Optimize Weight Loss At Obesityweek

Veru Receives Notification from The Nasdaq Stock Market

Third quarter 2024 earnings released: US$0.075 loss per share (vs US$0.075 loss in 3Q 2023)

Veru Inc. to Report Q3, 2024 Results on Aug 08, 2024

New major risk - Financial position

Veru Inc. to Present an Update of Veru's Phase 2B Clinical Program of Enobosarm to Augment Fat Loss and to Avoid Muscle Loss When Combined with GLP-1 Drugs for Weight Loss At the Jefferies Global Healthcare Conference

Chairman recently sold €227k worth of stock

High number of new and inexperienced directors

Veru Inc. to Report Q2, 2024 Results on May 08, 2024

Veru Inc. Enrolls First Patients in Phase 2b Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss

Veru Inc. Appoints Louis Aronne as Chief Medical Advisor and A Member of the Scientific Advisory Board

Veru Receives a Notification Letter from the Listing Qualifications Department of the Nasdaq Stock Market

Veru Inc. Announces New Scientific Advisory Board for Its Enobosarm Program for High Quality Weight Loss

Veru Inc. announced delayed 10-Q filing

Veru Inc. Announces U.S. Food and Drug Administration Clearance of Investigational New Drug Application for its Phase 2b Clinical Study

Veru Receives Non-Compliance Notice From Nasdaq

Veru Inc., Annual General Meeting, Mar 26, 2024

Veru Inc. to Report Q1, 2024 Results on Feb 08, 2024

Veru Submits IND Application to FDA for the Development of Enobosarm to Prevent Muscle Loss While Augmenting Fat Loss in Combination with Glp-1 Drugs for Weight Loss

New major risk - Shareholder dilution

Veru Inc. has completed a Follow-on Equity Offering in the amount of $33 million.

Veru Inc. has completed a Follow-on Equity Offering in the amount of $33 million.

Third quarter 2023 earnings released: US$0.075 loss per share (vs US$0.28 loss in 3Q 2022)

Veru Inc. Reports Muscle Data from 5 Clinical Studies of Enobosarm

Veru Reaches Agreement with FDA on New Phase 3 Clinical Trial for Sabizabulin for Broader Indication

Veru Inc. Announces Clinical Data from Its Discontinued Phase 3 ARTEST Clinical Trial of Enobosarm Monotherapy

New major risk - Financial position

Third quarter 2023 earnings released: EPS: US$0.072 (vs US$0.28 loss in 3Q 2022)

New minor risk - Market cap size

Veru Inc. to Report Q3, 2023 Results on Aug 10, 2023

High number of new and inexperienced directors

Veru Inc.(NasdaqCM:VERU) dropped from Russell 2000 Dynamic Index

Veru Announces Executive Appointments

Second quarter 2023 earnings released: US$0.48 loss per share (vs US$0.18 loss in 2Q 2022)

Veru Inc. announced that it expects to receive $100 million in funding from Lincoln Park Capital, LLC

Veru Reaches Agreement with FDA on Confirmatory Phase 3 Clinical Trial for Sabizabulin Treatment of Hospitalized COVID-19 Adult Patients at High Risk for ARDS

First quarter 2023 earnings released: US$0.46 loss per share (vs US$0.08 loss in 1Q 2022)

Veru Inc., Annual General Meeting, Mar 28, 2023

Veru Inc. to Report Q1, 2023 Results on Feb 09, 2023

Bragar Eagel & Squire, P.C. Announces Class Action Lawsuit Against Veru Inc

Veru Inc. Appoints David D. Ho as Chairman of Its Scientific Advisory Board

Wolf Haldenstein Adler Freeman & Herz LLP Announces Securities Class Action Lawsuit Against Veru Inc

Full year 2022 earnings released: US$1.05 loss per share (vs US$0.097 profit in FY 2021)

Veru Inc. Provides Update on FDA Advisory Committee Meeting Regarding Emergency Use Authorization of Sabizabulin to Treat Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome

Veru Inc. Announces Late-Breaker Oral Presentation of Sabizabulin Treatment for Hospitalized Adults with Covid-19 on Supplemental Oxygen At Infectious Disease Week 2022

Veru Inc. to Present Late-Breaker Oral Presentation of Sabizabulin Treatment for Hospitalized Adults with Covid-19 on Supplemental Oxygen At Infectious Disease Week 2022

Veru Inc. Receives Expedited Provisional Registration Regulatory Pathway for Sabizabulin Treatment in Hospitalized COVID-19 Patients by Australia’s Therapeutic Goods Administration

Veru Inc. Appoints Jason Davies as Executive Vice President General Manager of Europe, the Middle East and Africa, Latin America, and Asia Pacific

Third quarter 2022 earnings released: US$0.28 loss per share (vs US$0.034 loss in 3Q 2021)

Veru Inc. to Report Q3, 2022 Results on Aug 11, 2022

Uk’S Medicines and Healthcare Products Regulatory Agency (Mhra) Supports Expedited Review of Marketing Authorization Application for Sabizabulin Treatment in Hospitalized Covid-19 Patients of Veru Inc

Veru Announces New England Journal of Medicine Evidence Publication of Phase 3 Clinical Trial Results Demonstrating That Sabizabulin Treatment Significantly Reduced Deaths in High-Risk Hospitalized Covid-19 Patients

Veru Submits Emergency Use Authorization Application to U.S. FDA for Sabizabulin, Its Novel, Oral Antiviral and Anti-Inflammatory Drug Candidate for Hospitalized COVID-19 Patients At High Risk for ARDS

Veru Announces Presentation of Final Positive Phase 1b/2 Clinical Trial Results for Sabizabulin in Metastatic Castration Resistant Prostate Cancer at the 2022 American Society of Clinical Oncology Annual Meeting

Veru Inc. Appoints Joel Batten as Executive Vice President and Head of Its U.S. Infectious Disease Franchise, Effective May 23, 2022

Second quarter 2022 earnings released: US$0.18 loss per share (vs US$0.038 loss in 2Q 2021)

FDA Has Grants Veru Inc.'s Pre-Emergency Use Authorization (EUA) Meeting Date for Positive Sabizabulin Phase 3 COVID-19 Study

Veru Inc. Announces Results from Randomized Placebo-Controlled Phase 2 Study of Oral Sabizabulin

Veru Inc.'s Novel COVID-19 Drug Candidate Reduces Deaths by 55% in Hospitalized Patients in Interim Analysis of Phase 3 Study

Veru Inc. Announces the Presentation of Updated Data from the Phase 1B/2 Sabizabulin Study in Men with Metastatic Castration Resistant Prostate Cancer At the 2022 ASCO Genitourinary Cancers Symposium

Veru Inc. Reports That Independent Data Monitoring Committee for the Phase 3 Sabizabulin COVID-19 Clinical Study Recommends Continuing Study as Planned

First quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Investor sentiment improved over the past week

Veru Inc. Announces FDA Grant of Fast Track Designation for Sabizabulin for the Treatment of Hospitalized COVID-19 Patients At High Risk for Acute Respiratory Distress Syndrome

Veru Inc., Annual General Meeting, Mar 29, 2022

Veru Inc., Annual General Meeting, Mar 29, 2022

Investor sentiment improved over the past week

Veru Inc. Announces FDA Grant of Fast Track Designation for Enobosarm for the Treatment of AR+ ER+ HER2- Metastatic Breast Cancer

Veru Inc. Announces FDA Approval of ENTADFI

Veru Inc. Announces Presentation of Preclinical Evidence Supporting the Therapeutic Benefit of Enobosarm Alone or in Synergistic Combination with a CDK4/6 Inhibitor Against Palbociclib Resistant Metastatic Breast Cancer at the 2021 San Antonio Breast Cancer Symposium